NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…
Medical - Instruments & Supplies
JE, Saint Helier [HQ]
Ratios
11 Records · Starting from 2013Margins, Growth Rates In %
| Ratio | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | 32.30 | 35.21 | 37.71 | 44.16 | 68.59 | 67.73 | 74.78 | 78.46 | 78.53 | 78.64 | 74.81 | |
| Profit Margin | -746.89 | -520.87 | -337.24 | -159.06 | -34.83 | -25.62 | -2.06 | 4.01 | -10.91 | -17.20 | -40.65 | |
| Operating Margin | -622.25 | -517.47 | -314.31 | -139.12 | -22.22 | -13.57 | -0.26 | 4.30 | -8.29 | -16.64 | -45.72 | |
|
EPS Growth
|
- - | -4.67 | -227.68 | 58.04 | 54.55 | 1.43 | 89.22 | 368.82 | -380.00 | -57.14 | -121.59 | |
| EPS USD | -107.00 | -112.00 | -367.00 | -154.00 | -70.00 | -69.00 | -7.44 | 20.00 | -56.00 | -88.00 | -195.00 | |
| Return on Assets (ROA) | -40.96 | -68.45 | -36.31 | -46.74 | -23.24 | -18.71 | -1.51 | 1.88 | -5.12 | -7.77 | -18.06 | |
| Return on Equity (ROE) | -45.04 | -82.43 | -44.49 | -92.62 | -54.30 | -56.62 | -3.32 | 4.16 | -14.21 | -20.97 | -57.12 | |
| Return on Invested Capital (ROIC) | -37.62 | -82.02 | -39.54 | -52.47 | -23.71 | -17.81 | -0.18 | 2.51 | -4.71 | -9.21 | -24.10 | |
| Solvency | ||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 0.18 | 0.27 | 7.52 | 34.12 | 36.69 | 43.93 | 41.96 | 42.84 | 56.62 | 55.21 | 59.41 | |
| Debt/Equity | 0.20 | 0.33 | 9.21 | 67.60 | 85.72 | 132.97 | 92.37 | 94.58 | 157.18 | 149.12 | 187.86 | |
| Debt/EBITDA | 256.33 | 73.27 | 92.63 | 3.08 | -47.68 | -25.68 | 1,505.14 | 689.20 | -826.50 | -523.83 | -201.20 | |
|
Debt/Capitalization
|
0.20 | 0.33 | 8.43 | 40.34 | 46.15 | 57.08 | 48.02 | 48.61 | 61.12 | 59.86 | 65.26 | |
| Long-Term Debt/Capitalization | 0.20 | 0.33 | 8.43 | 40.34 | 46.15 | 57.08 | 42.89 | 48.24 | 58.36 | 56.98 | 62.19 | |
| Interest Debt per Share USD | 0.10 | 0.01 | 0.84 | 1.19 | 1.22 | 1.77 | 2.21 | 4.60 | 6.27 | 6.32 | 6.43 | |
| Debt Growth | - - | -7.23 | 7,095.33 | 316.64 | 1.16 | 53.34 | 9.58 | 171.57 | 29.50 | 1.58 | 2.05 | |
| Liquidity | ||||||||||||
| Current Ratio | 1,176.32 | 632.92 | 1,026.67 | 710.03 | 488.30 | 497.78 | 509.72 | 879.70 | 752.81 | 700.06 | 577.51 | |
| Quick Ratio | 1,152.55 | 608.24 | 978.88 | 640.03 | 440.19 | 459.54 | 479.84 | 845.44 | 735.12 | 681.24 | 551.45 | |
| Cash Ratio | 1,127.67 | 326.07 | 417.17 | 270.54 | 156.55 | 217.82 | 205.44 | 206.56 | 146.42 | 72.63 | 134.45 | |
| Operating Cash Flow Ratio | -300 | -400 | -300 | -200 | - - | - - | - - | - - | - - | - - | - - | |
| Turnover | ||||||||||||
| Inventory Turnover | 370.67 | 291.24 | 151.61 | 181.15 | 252.48 | 354.90 | 373.85 | 388.38 | 470.29 | 391.02 | 336.23 | |
| Receivables Turnover | 266.92 | 318.86 | 306.39 | 504.71 | 469.91 | 488.31 | 398.95 | 419.15 | 483.79 | 479.27 | 660.50 | |
| Payables Turnover | 68.18 | 100.03 | 123.01 | 252.14 | 323.20 | 299.72 | 239.96 | 198.52 | 158.23 | 134.83 | 135.90 | |
|
Asset Turnover
|
5.48 | 13.14 | 10.77 | 29.38 | 66.73 | 73.01 | 73.28 | 46.99 | 46.95 | 45.13 | 44.44 | |
| Fixed Turnover | 200.14 | 269.44 | 262.99 | 445.16 | 979.83 | 1,614.40 | 1,015.46 | 1,187.41 | 992.95 | 779.95 | 521.34 | |
| Coverage | ||||||||||||
| Interest Coverage | -900.52 | -195,502.44 | -4,382.47 | -1,942.34 | -383.28 | -249.59 | -6.66 | 161.64 | -1,288.75 | -2,685.15 | -7,016.27 | |
| Asset Coverage | 50,000 | 31,200 | 1,200 | 200 | 200 | 100 | 200 | 200 | 100 | 100 | 100 | |
| Cash Flow Coverage (CFGR) | -15,236.13 | -23,128.97 | -432.45 | -111.81 | -34.04 | -1.25 | 13.23 | 22.00 | 12.83 | 4.68 | -10.77 | |
| EBITDA Coverage | -900 | -190,700 | -4,300 | -1,900 | -300 | -200 | - - | 200 | -1,200 | -2,600 | -5,300 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | 100 | - - | - - | - - | |
| Market Prospects | ||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -4.88 | -5.08 | -16.41 | -19.63 | -3.45 | -2.07 | -0.09 | 0.11 | -0.75 | -1.21 | -13.04 | |
|
Price/Earnings (P/E)
|
-20.5123 | -19.6702 | -6.0923 | -5.0941 | -29.0072 | -48.3709 | -1,133.3621 | 881.7183 | -133.0872 | -82.9624 | -7.6719 | |
| Price/Earnings Growth (PEG) | - - | -420.94 | -2.68 | 8.78 | 53.18 | 3,385.96 | 1,270.34 | -239.07 | 35.02 | -145.18 | -6.31 | |
|
Price/Book (P/B)
|
923.88 | 1,621.49 | 271.02 | 471.84 | 1,575.01 | 2,738.67 | 3,762.44 | 3,665.08 | 1,891.81 | 1,740.11 | 438.19 | |
| Price/Tangible Book (P/TB) | 923.88 | 1,621.49 | 271.02 | 471.84 | 1,575.01 | 2,738.67 | 3,762.44 | 3,665.08 | 1,891.81 | 1,740.11 | 438.19 | |
| Price/Sales (P/S) | 15,320.35 | 10,245.54 | 2,054.52 | 810.29 | 1,010.38 | 1,239.33 | 2,332.42 | 3,532.82 | 1,451.46 | 1,427.35 | 311.86 | |
|
Price/Cash Flow (P/CF)
|
-3,010.48 | -2,137.59 | -680.57 | -624.24 | -5,398.21 | -164,847.34 | 30,782.15 | 17,615.16 | 9,383.94 | 24,934.54 | -2,165.95 | |
| Price/Free CF (P/FCF) | -2,816.69 | -2,072.85 | -617.11 | -536.21 | -4,416.40 | -35,848.91 | 50,785.30 | 20,747.30 | 13,255.33 | 81,408.76 | -1,581.64 | |
| Price/Operating CF (P/OCF) | -3,010.48 | -2,137.59 | -680.57 | -624.24 | -5,398.21 | -164,847.34 | 30,782.15 | 17,615.16 | 9,383.94 | 24,934.54 | -2,165.95 |